Feiya Ou

Feiya Ou

Auto-generated profile, based on publicly available information

Feiya Ou

Division of Immunobiology, Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2022 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
SFStephen T. Ferris
Stephen T. Ferris
RORay A. Ohara
Ray A. Ohara
FOFeiya Ou
Feiya Ou
RWRenee Wu
Renee Wu
XHXiao Huang
Xiao Huang
KMKenneth M. Murphy
Kenneth M. Murphy
As a cell-based cancer vaccine, dendritic cells (DC), derived from peripheral blood monocytes or bone marrow (BM) treated with GM-CSF (GMDC), were initially thought to induce antitumor immunity by presenting tumor antigens directly to host T cells. Subsequent work revealed that GMDCs do not directly prime tumor-specific T cells, but must transfer their antigens to host DCs. This reduces their advantage over strictly antigen-based strategies proposed as cancer vaccines. Type 1 conventional DCs (cDC1) have been reported to be superior to GMDCs as a cancer vaccine, but whether they act by transferring antigens to host DCs is unknown. To test this, we compared antitumor responses induced by GMDCs and cDC1 in Irf8 +32–/– mice, which lack endogenous cDC1 and cannot reject immunogenic fibrosarcomas. Both GMDCs and cDC1 could cross-present cell-associated antigens to CD8+ T cells in vitro. However, injection of GMDCs into tumors in Irf8 +32–/– mice did not induce antitumor immunity, consistent with their reported dependence on host cDC1. In contrast, injection of cDC1s into tumors in Irf8 +32–/– mice resulted in their migration to tumor-draining lymph nodes, activation of tumor-specific CD8+ T cells, and rejection of the tumors. Tumor rejection did not require the in vitro loading of cDC1 with antigens, indicating that acquisition of antigens in vivo is sufficient to induce antitumor responses. Finally, cDC1 vaccination showed abscopal effects, with rejection of untreated tumors growing concurrently on the opposite flank. These results suggest that cDC1 may be a useful future avenue to explore for antitumor therapy. See related Spotlight by Hubert et al., p. 918

11 July 2023 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
SKSunkyung Kim
Sunkyung Kim
JCJing Chen
Jing Chen
SJSuin Jo
Suin Jo
FOFeiya Ou
Feiya Ou
SFStephen T. Ferris
Stephen T. Ferris
KMKenneth M. Murphy
Kenneth M. Murphy
Cytokines produced in association with tumors can impair antitumor immune responses by reducing the abundance of type 1 conventional dendritic cells (cDC1), but the mechanism remains unclear. Here, we show that tumor-derived IL-6 generally reduces cDC development but selectively impairs cDC1 development in both murine and human systems through the induction of C/EBPβ in the common dendritic cell progenitor (CDP). C/EBPβ and NFIL3 compete for binding to sites in the Zeb2 −165 kb enhancer and support or repress Zeb2 expression, respectively. At homeostasis, pre-cDC1 specification occurs upon Nfil3 induction and consequent Zeb2 suppression. However, IL-6 strongly induces C/EBPβ expression in CDPs. Importantly, the ability of IL-6 to impair cDC development is dependent on the presence of C/EBPβ binding sites in the Zeb2 −165 kb enhancer, as this effect is lost in Δ1+2+3 mutant mice in which these binding sites are mutated. These results explain how tumor-associated IL-6 suppresses cDC1 development and suggest therapeutic approaches preventing abnormal C/EBPβ induction in CDPs may help reestablish cDC1 development to enhance antitumor immunity.

15 April 2026 in Nature
Verified
Journal Article
Closed access
PDF file
SJSuin Jo
Suin Jo
LLLijin Li
Lijin Li
CTChandrani Thakur
Chandrani Thakur
KTKevin A. Telfer
Kevin A. Telfer
HSHussein Sultan
Hussein Sultan
KMKenneth M. Murphy
Kenneth M. Murphy

7 February 2025 in Journal of Experimental Medicine
Verified
Journal Article
Closed access
SJSuin Jo
Suin Jo
RORay A. Ohara
Ray A. Ohara
DTDerek J. Theisen
Derek J. Theisen
SKSunkyung Kim
Sunkyung Kim
TLTiantian Liu
Tiantian Liu
KMKenneth M. Murphy
Kenneth M. Murphy
Priming CD8+ T cells against tumors or viral pathogens results largely from cross-presentation of exogenous antigens by type 1 conventional dendritic cells (cDC1s). Although monocyte-derived DCs and cDC2s can cross-present in vitro, their physiological relevance remains unclear. Here, we used genetic models to evaluate the role of cDC subsets in presentation of cell-associated and immune complex antigens to CD4+ and CD8+ T cells in vivo. For cell-associated antigens, cDC1s were necessary and sufficient to prime both CD4+ and CD8+ T cells. In contrast, for immune complex antigens, either cDC1 or cDC2, but not monocyte-derived DCs, could carry out cross-presentation to CD8+ T cells. Mice lacking cDC1 and vaccinated with immune complexes could cross-prime CD8+ T cells that were sufficient to mediate tumor rejection. Notably, this cross-presentation mediated by cDC2 was also WDFY4 dependent, similar to cross-presentation of cell-associated antigens by cDC1. These results demonstrate a previously unrecognized activity of WDFY4 in cDC2s and suggest a cross-presentation pathway shared by cDC subsets.

27 December 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
DADavid A. Anderson
David A. Anderson
FOFeiya Ou
Feiya Ou
SKSunkyung Kim
Sunkyung Kim
TMTheresa L. Murphy
Theresa L. Murphy
KMKenneth M. Murphy
Kenneth M. Murphy
During dendritic cell (DC) development, Myc expression in progenitors is replaced by Mycl in mature DCs, but when and how this transition occurs is unknown. We evaluated DC development using reporters for MYC, MYCL, and cell cycle proteins Geminin and CDT1 in wild-type and various mutant mice. For classical type 1 dendritic cells (cDC1s) and plasmacytoid DCs (pDCs), the transition occurred upon their initial specification from common dendritic cell progenitors (CDPs) or common lymphoid progenitors (CLPs), respectively. This transition required high levels of IRF8 and interaction with PU.1, suggesting the use of EICEs within Mycl enhancers. In pDCs, maximal MYCL induction also required the +41kb Irf8 enhancer that controls pDC IRF8 expression. IRF8 also contributed to repression of MYC. While MYC is expressed only in rapidly dividing DC progenitors, MYCL is most highly expressed in DCs that have exited the cell cycle. Thus, IRF8 levels coordinate the Myc-Mycl transition during DC development.

7 October 2024 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
FOFeiya Ou
Feiya Ou
TLTian-Tian Liu
Tian-Tian Liu
PDPritesh Desai
Pritesh Desai
SFStephen T. Ferris
Stephen T. Ferris
SKSunkyung Kim
Sunkyung Kim
KMKenneth M. Murphy
Kenneth M. Murphy